<p>A: Chemical structure of <sup>18</sup>F-ICMT-11. B: Dose-dependent changes in caspase 3/7 activity following carboplatin treatment. C: Dose-dependent changes in <sup>18</sup>F-ICMT-11 uptake in cells following carboplatin treatment. D: Correlation between caspase 3 activity and <sup>18</sup>F-ICMT-11 uptake in PC9 cells.</p
<p>shRNA-CLPTM1L transfected 95-D cells and control cells were treated with 50 uM cisplatin for 24 h...
<p>FLT uptake was analyzed one hour post injection in a carboplatin/paclitaxel treatment (n=6 tumors...
<p>DNA-mismatch repair in arrested cells recovering to the proliferating population is assumed to be...
<p>A: Time course of changes in caspase 3/7 activity following carboplatin treatment. B: Western blo...
<p>A: Carboplatin-induced growth inhibition in PC9 and A549 cells using a sulforhodamine B assay 72 ...
Tumour response to therapy is assessed primarily in the clinic by monitoring reductions in tumour si...
Tumour response to therapy is assessed primarily in the clinic by monitoring reductions in tumour si...
<p>Caspase activity was assessed by fluorimetric or luminometric assays, as described in the Materia...
Carboplatin is a derivative of cisplatin; it has a similar mechanism of action, but differs in terms...
<p>A, B: Tumour volumes recorded by calliper measurements of PC9 (A) and A549 tumours (B) pre- and p...
<p>(A) Time course (0–30 hours) fold increase in caspase 3/7, 8 and 9 activities of HT-29 cells post...
Cisplatin resistant (CP-r) cells often show decreased uptake of cisplatin in association with reduce...
This study measures the time-dependence of cellular caspase activation by anticancer drugs and compa...
<p>PBMCs from nine healthy volunteers were <i>ex vivo</i> treated (A) with cisplatin (0–300μg/ml) fo...
background: effective anticancer therapy is thought to involve induction of tumour cell death throug...
<p>shRNA-CLPTM1L transfected 95-D cells and control cells were treated with 50 uM cisplatin for 24 h...
<p>FLT uptake was analyzed one hour post injection in a carboplatin/paclitaxel treatment (n=6 tumors...
<p>DNA-mismatch repair in arrested cells recovering to the proliferating population is assumed to be...
<p>A: Time course of changes in caspase 3/7 activity following carboplatin treatment. B: Western blo...
<p>A: Carboplatin-induced growth inhibition in PC9 and A549 cells using a sulforhodamine B assay 72 ...
Tumour response to therapy is assessed primarily in the clinic by monitoring reductions in tumour si...
Tumour response to therapy is assessed primarily in the clinic by monitoring reductions in tumour si...
<p>Caspase activity was assessed by fluorimetric or luminometric assays, as described in the Materia...
Carboplatin is a derivative of cisplatin; it has a similar mechanism of action, but differs in terms...
<p>A, B: Tumour volumes recorded by calliper measurements of PC9 (A) and A549 tumours (B) pre- and p...
<p>(A) Time course (0–30 hours) fold increase in caspase 3/7, 8 and 9 activities of HT-29 cells post...
Cisplatin resistant (CP-r) cells often show decreased uptake of cisplatin in association with reduce...
This study measures the time-dependence of cellular caspase activation by anticancer drugs and compa...
<p>PBMCs from nine healthy volunteers were <i>ex vivo</i> treated (A) with cisplatin (0–300μg/ml) fo...
background: effective anticancer therapy is thought to involve induction of tumour cell death throug...
<p>shRNA-CLPTM1L transfected 95-D cells and control cells were treated with 50 uM cisplatin for 24 h...
<p>FLT uptake was analyzed one hour post injection in a carboplatin/paclitaxel treatment (n=6 tumors...
<p>DNA-mismatch repair in arrested cells recovering to the proliferating population is assumed to be...